In the breast cancer patients with the CHEK2 PV in our study, 91.7% had estrogen-receptor-positive cancer, 78.8% had progesterone-receptor-positive cancer and 68.8% had a negative epidermal growth factor receptor 2 (HER2)-status. The gene discussed is PGR; the disease is breast carcinoma.